Steroid-induced diabetes in oncology Review article
Article Sidebar
Main Article Content
Abstract
Patients with neoplasms belong to the group of higher risk for developing steroid-induced diabetes. The rules of diagnosis of this form of diabetes do not differ from others of its type, but the course and treatment differ significantly from the clinical picture observed in type 1 and 2. It results from different schemes of glicocorticotherapy, differentiated state of the patient dependent on tumor stage and presence of comorbidities. However, note that in a patient with hyperplastic process, diabetes can occur regardless of the administration of diabetogenic agents, which can be exemplified by the presence of diabetes or pre-diabetic status in a patient with pancreatic cancer. Another clinical situation occurs if the patient with diabetes has to be treated with glicocorticosteroids due to neoplasmatic process. It should be emphasized as an inverse relationship eg. stimulation of tumor growth by processes occurring in type 2 diabetes particularly with concomitant visceral obesity. Such a patient will be more prone to induce hyperglycaemia during glicocorticotherapy. The atricle presents the practical aspects of treatment of hyperglycemia in glicocorticotherapy.
Downloads
Metrics
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
2. Chopkin S.R., Kelly K.L., Ruderman N.B.: Hormone-fuel interrelationships: fed state, starvation and diabetes mellitus. W: Joslin’s diabetes mellitus. Kahn C.R., Weir G.C. (red.). 1994: 97.
3. Cigolini M., Smith U.: Human adipose tissue in culture. Studies on the insulin-antagonistic effect of glucocorticoids. Metabolism 1979; 28: 502-510.
4. Berg J.M., Tymoczko J.L., Stryer L.: Metabolizm glikogenu W: Biochemia. Warszawa 2005: 589-599.
5. Online: www.diabetes.org.uk.
6. Zalecenia kliniczne dotyczące postępowania u chorych na cukrzycę 2011, Stanowisko Polskiego Towarzystwa Diabetologicznego. Diabetologia Praktyczna, 2011; 12: suplement A.
7. Donihi A.C., Raval D., Saul M.: Prevalence and predictors of corticoid-related hyperglycemia in hospitalized patients. Endocr. Pract. 2006; 12: 358-362.
8. Hyperglycaemic management of patients during the use of steroid therapy [online, dostęp 1.04.10.2010]: 6.